EYLEA Injection Demonstrates Significantly Greater Gains In Visual Acuity than Both Bevacizumab And Ranibizumab In NIH-Sponsored Diabetic Macular Edema Study

By: via Benzinga
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that in the National Institutes of Health (NIH) sponsored, Diabetic ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.